Sionna Therapeutics announced it is laying off 46% of its workforce after an unexpected cystic fibrosis trial failure. The job cuts come as the company reorganizes its development priorities and looks for a way forward following the setback. The move highlights how quickly resource allocation is shifting for smaller biotechs when add-on or confirmatory programs miss key expectations. With early-stage cash conservation now becoming a dominant strategy, companies are prioritizing surviving programs while reassessing pipeline risk. The staffing reduction also underscores the growing dependence of mid-sized biotechs on financing windows and milestone completion, particularly for asset-heavy development portfolios.